Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MET amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	tepotinib Sensitive: A2 - Guideline tepotinib Sensitive : A2	tepotinib Sensitive: A2 - Guideline tepotinib Sensitive : A2
MET amplification	Renal Cell Carcinoma	MET amplification	Renal Cell Carcinoma	savolitinib Sensitive: A2 - Guideline savolitinib Sensitive : A2	savolitinib Sensitive: A2 - Guideline savolitinib Sensitive : A2
MET amplification	Gastroesophageal Junction Adenocarcinoma	MET amplification	Gastroesophageal Junction Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Gastric Adenocarcinoma	MET amplification	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria bevacizumab + crizotinib Sensitive : C2	bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria bevacizumab + crizotinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria gefitinib + CT053PTSA Sensitive : C2	gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria gefitinib + CT053PTSA Sensitive : C2
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2
MET amplification	Lung Cancer	MET amplification	Lung Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	APL-101 Sensitive: C2 – Inclusion Criteria APL-101 Sensitive : C2	APL-101 Sensitive: C2 – Inclusion Criteria APL-101 Sensitive : C2